| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
|
Medicine details |
|
| Medicine name | venetoclax (Venclyxto®) |
| Formulation | 10 mg, 50 mg, 100 mg film-coated tablet |
| Reference number | 3524 |
| Indication | In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy |
| Company | AbbVie Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/12/2018 |
| NICE guidance | TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |